| Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High Blood Press Cardiovasc Prev | Pooled analysis | 2026 |
| Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Ann Intern Med | Pooled analysis | 2026 |
| Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ | Pooled analysis | 2026 |
| Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.Eur J Prev Cardiol | Pooled analysis | 2026 |
| Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.Endocrinol Diabetes Metab | Pooled analysis | 2026 |
| Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.Obesity (Silver Spring) | Pooled analysis | 2025 |
| Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.J Clin Endocrinol Metab | Pooled analysis | 2025 |
| Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Endocrinol Diabetes Metab | Pooled analysis | 2025 |
| Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis.Acta Diabetol | Pooled analysis | 2025 |
| Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.Diabetes Technol Ther | Pooled analysis | 2025 |
| Efficacy of GLP-1 Receptor Agonist-Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta-Analysis of Randomized Controlled Trials.J Diabetes | Pooled analysis | 2025 |
| Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.J Diabetes | Pooled analysis | 2025 |
| Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.Front Endocrinol (Lausanne) | Pooled analysis | 2025 |
| Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.Expert Rev Clin Pharmacol | Pooled analysis | 2025 |
| Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.Metabolism | Pooled analysis | 2024 |
| Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes Obes Metab | Random groups | 2026 |
| Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.J Clin Endocrinol Metab | Random groups | 2026 |
| Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet | Random groups | 2026 |
| Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes Obes Metab | Random groups | 2025 |
| Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nat Med | Random groups | 2024 |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet | Random groups | 2023 |
| LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet | Random groups | 2022 |
| Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.Diabetes Obes Metab | No random groups | 2025 |
| Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.JCEM Case Rep | Case reports | 2026 |
| Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.Cureus | Case reports | 2026 |
| GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases.Eur J Pharmacol | Review of studies | 2026 |
| The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.J Diabetes Metab Disord | Review of studies | 2026 |
| The First Triple Agonist for Antiobesity: Retatrutide.Cardiol Rev | Review of studies | 2026 |
| Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search.Rev Endocr Metab Disord | Review of studies | 2026 |
| Medical treatments for obesity: what does the future have in store?J Clin Endocrinol Metab | Review of studies | 2026 |
| Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.Aesthet Surg J | Review of studies | 2026 |
| GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Acta Diabetol | Review of studies | 2026 |
| From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.Front Pharmacol | Review of studies | 2026 |
| Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.Pharmaceutics | Review of studies | 2026 |
| Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.Pharmaceutics | Review of studies | 2026 |
| Single or multiple nutritional hormone receptor modulators for chronic kidney disease.Clin Kidney J | Review of studies | 2026 |
| Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract | Review of studies | 2026 |
| Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Ann Intern Med | Review of studies | 2026 |
| GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review.Int J Mol Sci | Review of studies | 2026 |
| The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?Med Sci (Basel) | Review of studies | 2026 |
| Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.Cureus | Review of studies | 2026 |
| Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring.Clin Oral Investig | Review of studies | 2026 |
| Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.Diabetes Metab J | Review of studies | 2026 |
| Pharmacological management of obesity: Current landscape and emerging therapies.Indian J Pharmacol | Review of studies | 2026 |
| The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.Pharmacol Res | Review of studies | 2026 |
| Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.Biomedicines | Review of studies | 2026 |
| GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.Curr Psychiatry Rep | Review of studies | 2026 |
| Anti-Obesity Medications in Longevity and Aesthetic Medicine.J Clin Med | Review of studies | 2026 |
| From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals.Curr Med Res Opin | Review of studies | 2026 |
| Beyond weight loss: multisystem benefits of obesity medications.Lancet Diabetes Endocrinol | Review of studies | 2026 |
| Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Incretin analogues as cardiovascular agents: a state-of-the-art review.Front Endocrinol (Lausanne) | Review of studies | 2026 |
| Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.Cureus | Review of studies | 2026 |
| Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.Front Pharmacol | Review of studies | 2026 |
| GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.Diabetes Metab Syndr Obes | Review of studies | 2026 |
| Synergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.Curr Obes Rep | Review of studies | 2026 |
| Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabol Open | Review of studies | 2026 |
| Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.Clin Nutr ESPEN | Review of studies | 2026 |
| Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.Eur J Clin Pharmacol | Review of studies | 2026 |
| Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.Pharmaceutics | Review of studies | 2026 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.Medicina (Kaunas) | Review of studies | 2026 |
| Metabolic inflammation at the adipose-brain axis.Front Physiol | Review of studies | 2026 |
| Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.Indian J Med Res | Review of studies | 2026 |
| Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions.Liver Int | Review of studies | 2026 |
| Retatrutide in type 2 diabetes mellitus and obesity: an overview.Expert Rev Clin Pharmacol | Review of studies | 2026 |
| Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders.Clin Mol Hepatol | Review of studies | 2026 |
| New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.Nutrients | Review of studies | 2026 |
| Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.Curr Diab Rep | Review of studies | 2026 |
| Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocr Rev | Review of studies | 2026 |
| Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.Eur J Med Chem | Review of studies | 2026 |
| The role of GIP in carbohydrate metabolism: Implications in the development of therapies for T2DM, a narrative review.Histol Histopathol | Review of studies | 2026 |
| Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.Eur J Med Res | Review of studies | 2026 |
| Cardiovascular effects of incretin receptor agonists: beyond glycemic control.Can J Physiol Pharmacol | Review of studies | 2026 |
| [An historical overview of GLP-1/GIP incretins. From hormone to "swiss-army knife" medications].Biol Aujourdhui | Review of studies | 2026 |
| The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.Clin Pharmacol Drug Dev | Review of studies | 2026 |
| IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.Pharmacol Res | Review of studies | 2026 |
| Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.Maedica (Bucur) | Review of studies | 2025 |
| Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.Diabetes Obes Metab | Review of studies | 2025 |
| Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.J Obes | Review of studies | 2025 |
| Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.J Clin Med | Review of studies | 2025 |
| Medical Management of Obesity: A Comprehensive Review of Food and Drug Administration (FDA)-Approved and Investigational Therapies.Cureus | Review of studies | 2025 |
| Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.Medicina (Kaunas) | Review of studies | 2025 |
| Weight management treatment in obesity.Med Clin (Barc) | Review of studies | 2025 |
| Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.Acad Emerg Med | Review of studies | 2025 |
| Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.World J Gastroenterol | Review of studies | 2025 |
| The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: A Scoping Review.Cureus | Review of studies | 2025 |
| Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs.World J Diabetes | Review of studies | 2025 |
| Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.Panminerva Med | Review of studies | 2025 |
| Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.World J Cardiol | Review of studies | 2025 |
| Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies.Medicines (Basel) | Review of studies | 2025 |
| Review: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.Drugs Context | Review of studies | 2025 |
| Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.J Basic Clin Physiol Pharmacol | Review of studies | 2025 |
| Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.Pharmacol Rev | Review of studies | 2025 |
| Retatrutide-A Game Changer in Obesity Pharmacotherapy.Biomolecules | Review of studies | 2025 |
| Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides | Review of studies | 2025 |
| [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].Nervenarzt | Review of studies | 2025 |
| Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.Pol Arch Intern Med | Review of studies | 2025 |
| Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review.Cureus | Review of studies | 2025 |
| The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.Expert Opin Investig Drugs | Review of studies | 2025 |
| What is the pipeline for future medications for obesity?Int J Obes (Lond) | Review of studies | 2025 |
| Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.Proc (Bayl Univ Med Cent) | Review of studies | 2025 |
| Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.Ann Intern Med | Review of studies | 2025 |
| Triple Agonism Based Therapies for Obesity.Curr Cardiovasc Risk Rep | Review of studies | 2025 |
| Emerging pharmacotherapies for obesity: A systematic review.Pharmacol Rev | Review of studies | 2025 |
| Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.Annu Rev Pharmacol Toxicol | Review of studies | 2025 |
| The power of three: Retatrutide's role in modern obesity and diabetes therapy.Eur J Pharmacol | Review of studies | 2024 |
| Why are we still in need for novel anti-obesity medications?Lancet Reg Health Eur | Review of studies | 2024 |
| The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.Metabolism | Review of studies | 2024 |
| Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile.J Mol Histol | In animals | 2026 |
| Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.Behav Brain Res | In animals | 2026 |
| Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.Nat Metab | In animals | 2026 |
| GIPR:GCGR co-agonism restores normal weight in obese rodents.Mol Metab | In animals | 2026 |
| Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.Obesity (Silver Spring) | In animals | 2026 |
| Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.Psychopharmacology (Berl) | In animals | 2026 |
| Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.Int J Obes (Lond) | In animals | 2026 |
| Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.Am J Physiol Gastrointest Liver Physiol | In animals | 2025 |
| Contractile effects of retatrutide in isolated mouse atrial preparations.Naunyn Schmiedebergs Arch Pharmacol | In animals | 2025 |
| Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.Endocrine | In animals | 2025 |
| LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.Cell Metab | In animals | 2022 |
| Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.Rapid Commun Mass Spectrom | Other paper | 2026 |
| Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.N Engl J Med | Other paper | 2026 |
| Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.J Chromatogr A | Other paper | 2026 |
| Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?Lancet | Other paper | 2026 |
| Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.JAMA | Other paper | 2026 |
| Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide.JAMA Netw Open | Other paper | 2026 |
| Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.BMJ | Other paper | 2026 |
| Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.N Engl J Med | Other paper | 2026 |
| Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes Obes Metab | Other paper | 2026 |
| Future GLP-1 receptor co-agonists and their cardiac effects.Naunyn Schmiedebergs Arch Pharmacol | Other paper | 2026 |
| Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.iScience | Other paper | 2026 |
| Incretin-based therapies in diabetic kidney disease: toward integrated cardio-kidney-metabolic disease modification.Kidney Res Clin Pract | Other paper | 2026 |
| Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.BMJ Med | Other paper | 2026 |
| Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception.Cardiovasc Diabetol | Other paper | 2026 |
| Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.BMJ | Other paper | 2026 |
| Integrating glucagon-like peptide-1 receptor agonists into dermatology practice: Safety and monitoring strategies.Clin Dermatol | Other paper | 2026 |
| Retatrutide effects on diabetic rats' cognition.Lab Anim (NY) | Other paper | 2026 |
| Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?BMJ | Other paper | 2026 |
| A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.Org Lett | Other paper | 2026 |
| Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.BMJ | Other paper | 2026 |
| Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.Nephrol Dial Transplant | Other paper | 2026 |
| Kynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation.Nat Commun | Other paper | 2026 |
| Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.Cardiol Rev | Other paper | 2026 |
| Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.Diabetol Metab Syndr | Other paper | 2026 |
| Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.Cardiol Rev | Other paper | 2026 |
| Development of the Weight and Emotions Scale (WES).Obes Sci Pract | Other paper | 2026 |
| [Nephrology : what's new in 2025].Rev Med Suisse | Other paper | 2026 |
| Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.Adv Ther | Other paper | 2026 |
| Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.Diabetes Obes Metab | Other paper | 2026 |
| Inotropic effects of retatrutide in isolated human atrial preparations.Naunyn Schmiedebergs Arch Pharmacol | Other paper | 2026 |
| Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.Obes Pillars | Other paper | 2025 |
| Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects.J Med Chem | Other paper | 2025 |
| The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.Kidney Int Rep | Other paper | 2025 |
| Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.Obes Pillars | Other paper | 2025 |
| Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.Adv Sci (Weinh) | Other paper | 2025 |
| Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.NPJ Metab Health Dis | Other paper | 2025 |
| Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado.J Pharm Policy Pract | Other paper | 2025 |
| The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.J Pharm Technol | Other paper | 2024 |
| Retatrutide.Clin Diabetes | Other paper | 2024 |
| Recent advances in peptide-based therapies for obesity and type 2 diabetes.Peptides | Other paper | 2024 |
| Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond.Metabolism | Other paper | 2024 |
| At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide.JAMA | Other paper | 2024 |
| The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying.Diabetes Obes Metab | Other paper | 2023 |
| Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.JAMA | Other paper | 2023 |
| Retatrutide: a triple incretin receptor agonist for obesity management.Expert Opin Investig Drugs | Other paper | 2023 |
| Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943.STAR Protoc | Other paper | 2023 |
| Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?Expert Opin Investig Drugs | Other paper | 2023 |